CD73 as a potential opportunity for cancer immunotherapy. (1st February 2019)

• Record Type: Journal Article
• Authors: Ghalamfarsa, Ghasem; Kazemi, Mohammad Hossein; Raoofi Mohseni, Sahar; Masjedi, Ali; Hojjat-Farsangi, Mohammad; Azizi, Gholamreza; Yousefi, Mehdi; Jadidi-Niaragh, Farhad
• Is Part Of: Expert opinion on therapeutic targets. Volume 23:Number 2(2019:Feb.)
• Page Start: 127
• Page End: 142
• Publication Date: 2019-02-01
• Subjects: CD73 -- cancer immunotherapy -- adenosine -- adenosine receptor; Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1080/14728222.2019.1559829
• Languages: English
• ISSNs: 1744-7631

Abstract

ABSTRACT: Introduction : Cancer cells apply various mechanisms to induce and enhance immune escape. The complex network of immune-response modulating factors in the tumor microenvironment is a reason for the difficulties encountered when attempting to treat many cancers. Adenosine is a potent immune-modulating factor that can be generated through the degradation of ATP by cooperative action of NTPDase1 (CD39) and ecto-5ʹ-nucleotidase (CD73) molecules. Overexpression of CD73 on tumor and immune cells leads to the presence of a high concentration of this factor in the tumor region. Upregulation of CD73 is associated with the overproduction of adenosine; it suppresses antitumor immune responses and helps proliferation, angiogenesis, and metastasis. Areas covered : We attempt to clarify the immunobiology of CD73 in association with its role in cancer development, angiogenesis, and metastasis. Moreover, we have reviewed CD73-targeting studies and highlighted CD73 as a potent target for cancer immunotherapy. Expert opinion : It seems that blockade of CD73, in combination with immune checkpoint inhibitors such as anti-PD-L1 and anti-CTLA-4, can be a novel promising therapeutic strategy that can be evaluated in the future trials.